CN Patent

CN108135871B — 阻断疾病的泛素化-蛋白酶体系统的胺萘醌化合物及医药组合物

Assigned to Bo Wei Pharmaceutical Biotechnology Co ltd · Expires 2022-11-04 · 4y expired

What this patent protects

本发明涉及用于阻断疾病的泛素化‑蛋白酶体系统的具有低细胞毒性的新颖化合物。因此，这些化合物可用于治疗包括(但不限于)癌症、神经退化疾病、发炎病症、自体免疫病症及代谢失调的病症。

USPTO Abstract

本发明涉及用于阻断疾病的泛素化‑蛋白酶体系统的具有低细胞毒性的新颖化合物。因此，这些化合物可用于治疗包括(但不限于)癌症、神经退化疾病、发炎病症、自体免疫病症及代谢失调的病症。

Drugs covered by this patent

Patent Metadata

Patent number
CN108135871B
Jurisdiction
CN
Classification
—
Expires
2022-11-04
Drug substance claim
No
Drug product claim
No
Assignee
Bo Wei Pharmaceutical Biotechnology Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.